Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
116
resultados
Última actualización
02/04/2026 [07:20:00]
Resultados 50 a 75 de 116
Resumen de: KR20260015111A
본 개시는 편두통 진단을 위한 정보 제공 방법에 관한 것으로서, 보다 상세하게는 생물학적 시료에서 제멜라 헤몰리산스, 센티페다 페리오돈티, 카르디오박테리움 발바룸, 카토넬라 모르비 및 셀레노모나스 녹시아로 이루어진 군에서 선택된 적어도 하나의 박테리아의 상대적 풍부도를 측정하는 단계를 포함함으로써 환자의 통증 또는 거부감 없이 정확하고 신속한 편두통 진단을 가능하게 하는 방법에 관한 것이다.
Resumen de: CN121427969A
The invention discloses a hermetia illucens antibacterial peptide Hill198 and genetic recombination bacillus subtilis thereof, and belongs to the technical field of genetic engineering and microorganism application. A bacillus subtilis protease deficient strain WB800N is taken as a starting strain and is transferred into a recombinant expression vector pHT43-Hill198, and recombinant bacillus subtilis for efficiently secreting and expressing the Hill198 protein is obtained by virtue of IPTG (isopropyl-beta-d-thiogalactoside) induction. After the recombinant strain is subjected to induced expression, the fermentation supernatant of the recombinant strain has obvious inhibitory activity on escherichia coli O157: H7 and salmonella typhimurium. The recombinant plasmid still keeps stable inheritance after continuous passage for 30 generations, and insertion of exogenous genes does not affect normal growth characteristics of host bacteria. The recombinant bacterium can be used as a feed additive and is used for preventing and treating intestinal diarrhea diseases of livestock and poultry and aquatic animals caused by gram-negative bacteria such as escherichia coli.
Resumen de: CN121427773A
The invention discloses lactobacillus johnsonii for preventing and treating pullorum disease salmonellosis and application of the lactobacillus johnsonii, and belongs to the field of microorganisms. According to the invention, a strain of Lactobacillus johnsonii LMZ8 is separated and screened, and the preservation number of the strain of Lactobacillus johnsonii LMZ8 is GDMCC No: 66614. The lactobacillus johnsonii LMZ8 is good in acid resistance and has certain tolerance to high-concentration cholate. Experimental results show that the lactobacillus johnsonii LMZ8 can effectively inhibit the growth of various pathogenic bacteria such as salmonella typhimurium and salmonella enteritidis, especially has a prominent inhibition effect on five strains of multi-drug-resistant salmonella pullorum with no same drug resistance spectrum, can effectively prevent and treat the pullorum disease caused by salmonella pullorum, and improves the growth performance of chicks. The lactobacillus johnsonii LMZ8 shows remarkable development potential in the aspects of preventing and controlling food-borne pathogenic bacteria and preventing and treating diseases such as pullorum disease, and has a wide development prospect.
Resumen de: CN121421088A
The invention discloses a traditional Chinese medicine waste resource feed additive capable of promoting growth and enhancing immunity and a preparation method of the traditional Chinese medicine waste resource feed additive. The feed additive is prepared on the basis of medicinal and edible byproducts such as honeysuckle leaf waste, astragalus residues, pericarpium citri reticulatae peel scraps, lycium barbarum seed squeezing residues and ginger peel which are generated in the traditional Chinese medicine processing process. After biotransformation treatments of solid state fermentation, hydrolysis, ultrasonic wall breaking, extraction and the like, the mixture is compounded with yeast cell walls and a plant-based carrier. Feeding test results show that the feed additive can effectively improve lysozyme activity, antioxidant enzyme activity and immune cell phagocytic ability of livestock and poultry, reduce morbidity and death rate caused by common bacterial diseases (such as escherichia coli, salmonella, streptococcus and the like), promote daily gain, improve feed conversion rate and improve overall growth performance. According to the invention, high-valued utilization of waste resources with homology of medicine and food can be realized, a novel functional feed additive is provided for antibiotic-free, green and efficient breeding, and the feed additive is suitable for large-scale animal husbandry production.
Resumen de: CN121426096A
The invention discloses a preparation method of Tieguanyin tea residue carbon dots, which comprises the following steps: S1, tea residue pretreatment: soaking Tieguanyin tea leaves in distilled water according to a mass-to-volume ratio of 2.5 g/ml-5 g/ml, filtering, collecting tea residues, and drying the tea residues to obtain tea residue powder; s2, tea residue carbon dot synthesis: uniformly mixing the tea residue powder obtained in the step S1 with water according to a mass volume ratio of 1g: (25-30) ml to obtain a tea residue suspension, transferring the tea residue suspension into a polytetrafluoroethylene reaction kettle, carrying out a hydrothermal reaction, and cooling to room temperature to obtain a reaction solution; s3, primary purification of the tea residue carbon dots: performing suction filtration on the reaction solution obtained in the step S2 to obtain a clear and transparent solution, and performing concentration and centrifugation to obtain supernate. And S4, secondary purification of the tea residue carbon dots: filtering, dialyzing and freeze-drying the supernate obtained in the step S3 to obtain the Tieguanyin tea residue carbon dots. The invention further discloses the tea residue carbon dots prepared by the method and application of the tea residue carbon dots. The raw materials are cheap and easy to obtain, the process is simple, green and environment-friendly, and the prepared Tieguanyin tea residue carbon dots have a good antibacterial effect and
Resumen de: WO2025003119A1
The invention relates to a method for detecting and confirming at least one Shiga toxin-producing Escherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.
Resumen de: CN121426898A
The invention provides a broad-spectrum antibacterial peptide KVL4 as well as a preparation method and application thereof, and belongs to the technical field of biology, and the amino acid sequence of the broad-spectrum antibacterial peptide KVL4 is shown as SEQ ID No.1. Design is carried out on the basis of an alpha-helical peptide template (abcdefg) n, n = 4, positions a, d and f are hydrophobic amino acids, and Val, Leu and Trp are adopted in sequence; positive charge amino acid Lys is adopted at positions b, c and e; and negative charge amino acid Glu is adopted at the position g to promote spiral association. The antibacterial peptide KVL4 has an inhibition effect on various bacteria such as escherichia coli, salmonella typhimurium and staphylococcus aureus, and the average antibacterial activity is as low as 5.84 mu M. And the high-concentration KVL4 shows good biocompatibility on both human red blood cells and porcine jejunum epithelial cells IPEC-J2. In conclusion, the antibacterial peptide KVL4 is an antibacterial peptide with relatively high application potential.
Resumen de: CN121427886A
The invention discloses an antibacterial peptide fragment intercepted from a mined fly IDGF4 protein and application of the antibacterial peptide fragment in preparation of antibacterial drugs. According to the invention, oligopeptide fragments at different parts in the collected fly IDGF4 protein are screened, three candidate peptides are obtained through chemical synthesis, the antibacterial performance of the candidate peptides is systematically evaluated, antibacterial experiment results show that the oligopeptide with the amino acid sequence shown as SEQ ID No.2 can effectively inhibit the growth of salmonella and staphylococcus aureus under the concentration of 1mg/mL, and the oligopeptide with the amino acid sequence shown as SEQ ID No.2 can effectively inhibit the growth of salmonella and staphylococcus aureus under the concentration of 1mg/mL. The antibacterial effect of the peptide is confirmed in inhibition zone experiments, enzyme-labeled turbidimetry and growth curve monitoring, and the peptide shows stable and remarkable antibacterial activity, which indicates that the peptide can be used as a novel antibacterial molecule. The invention provides a new candidate sequence for developing the antibacterial peptide with high efficiency and low drug resistance risk, and has application potential in the aspect of preparing clinical antibacterial drugs.
Resumen de: CN121428177A
The invention relates to the technical field of biological detection, and discloses an oligonucleotide composition, a kit and application. The composition disclosed by the invention can be used for rapidly and simultaneously detecting salmonella, shigella, entamoeba histolytica, vibrio cholerae, hepatitis A virus and hepatitis E virus in a sample with high specificity, and has relatively high sensitivity and stability. Compared with the traditional detection methods such as pathogen separation, genome sequencing and the like, the efficiency of identifying and detecting salmonella, shigella, entamoeba histolytica, vibrio cholerae, hepatitis A virus and hepatitis E virus by adopting the composition disclosed by the invention is effectively improved, the detection process is simple and convenient to operate, and the composition is suitable for large-scale popularization and application.
Resumen de: US20260027165A1
The present disclosure relates to a recombinant expression vector for secretion of chlorotoxin and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising a flgM gene and a chlorotoxin gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain.
Resumen de: US20260028377A1
The present invention relates to a gene construct characterized by encoding a fusion protein of flgM and Strep-tag through the linkage of an anti-sigma factor flgM gene and a gene encoding Strep-tag, enabling the expression of Strep-tag on the surface of an anti-cancer strain that can target tumor sites and stimulate immune activity, and to an anti-cancer adjuvant and tumor imaging agent that, when transformed by this construct, exhibits anti-cancer activity itself and can be effectively utilized in the diagnosis and treatment of tumor cells together with anti-cancer substances or contrast agents labeled with substances specifically interacting with Strep-tag.
Resumen de: WO2026024938A1
Methods of reducing or preventing intrauterine transmission of Salmonella Dublin in a subject, typically a cow, are provided. The methods include a first administration, and optionally second or more administrations, to a pregnant cow of an effective amount of an immunogenic composition to induce an immune response against S. Dublin in the cow. In some forms, the cow is infected with S. Dublin. In some forms, two or more cows are treated in parallel, for example, all cows that inseminated or otherwise became pregnant in parallel. Typically, the first administration, and optionally second or more administrations, are administered to the cow at a time(s) that reduces intrauterine transmission of S. Dublin infection from the cow to one or more of her calves compared to unvaccinated control cows and/or cows administered according to a different administration regimen. Exemplary methods of administration are provided.
Resumen de: WO2024197078A2
Provided herein are compositions and methods for treating benign nervous system tumors, including schwannomas, using attenuated mutants of Salmonella typhimurium comprising a spiC deletion, and, optionally, one or more checkpoint inhibitors.
Resumen de: GB2700365A
Method of performing SBA assay comprising: preparing media and buffer; preparing bacterial stock with a mother culture stock, media and buffer; diluting bacterial stock with buffer to obtain a diluted bacterial stock; adding test serum, complement, diluted bacterial stock, and buffer to form an assay solution; incubating assay solution, spotting it on an agar plate and incubating the plate; calculating antibody titre to determine the serum bactericidal activity. Kit or system for performing said SBA assay wherein they contain said media, buffer, bacterial stock and complement and optionally a package insert or label providing instructions to perform the SBA assay. Method for performing a serum bactericidal assay comprising preparing a bacterial stock with a mother culture stock and media, diluting the bacterial stock 1:100-1:6000 with buffer to obtain diluted bacterial stock, adding test serum, complement, diluted bacterial stock, and buffer to form an assay solution; incubating the assay solution, spotting it on an agar plate and incubating the plate; calculating antibody titre to determine the serum bactericidal activity. Figure 1
Resumen de: CN121406806A
The invention belongs to the technical field of biological detection, and particularly relates to a dual MIRA detection method for type A clostridium botulinum and staphylococcus aureus for a portable reagent card incubator. The double colloidal gold type MIRA method established by the invention has good specificity on type A clostridium botulinum and staphylococcus aureus, and has no cross reaction with six strains such as pasteurella multocida, klebsiella pneumoniae and salmonella. The lowest detection limits of the method on the staphylococcus aureus and the A-type clostridium botulinum are 2.94 * 100 copies/mu L and 2.27 * 100 copies/mu L respectively. The optimized double colloidal gold type MIRA method can be successfully applied to a reagent card incubator. The detection method disclosed by the invention has the advantages of good specificity, high sensitivity, simplicity in operation, short time consumption and the like.
Resumen de: CN121405721A
The invention relates to the field of antibacterial agents, in particular to marine bioalkali biquaternary ammonium salt as well as a pharmaceutical composition and antibacterial application thereof. The novel biquaternary ammonium salt is constructed based on marine bioalkali eudistomin N through a pharmacophore splicing strategy, has a structural formula as shown in a formula I, has broad-spectrum antibacterial activity, is used for inhibiting growth of bacteria such as staphylococcus aureus, methicillin-resistant staphylococcus aureus, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa and salmonella enteritidis, and can be used for inhibiting growth of bacteria such as staphylococcus aureus, methicillin-resistant staphylococcus aureus, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa and salmonella enteritidis. The compound is particularly used for inhibiting escherichia coli ATCC 8739 or resisting klebsiella pneumoniae ATCC 10031.
Resumen de: CN121406536A
The invention provides anti-PDCoV combined lactobacillus salivarius LSM237 and application thereof, and belongs to the technical field of microorganisms. The preservation number of the combined lactobacillus salivarius LSM237 is CCTCC (China Center For Type Culture Collection) NO: M 20252371. The probiotics are symbiotic probiotics in intestinal tracts, have the characteristics of high acid production capacity, acid resistance and bile salt resistance, have high endurance capacity to artificial gastrointestinal fluid, and can inhibit serratia marcescens, escherichia coli, staphylococcus aureus and salmonella typhimurium. The combined lactobacillus salivarius LSM237 has a remarkable anti-PDCoV effect, the anti-PDCoV infection capability of piglets can be improved, and clinical symptoms caused by PDCoV infection can be relieved. The combined lactobacillus salivarius LSM237 can regulate the immune system of a body and maintain the balance of intestinal flora of the body, can provide an application basis for developing a novel micro-ecological viable bacterium preparation for treating viral infection diseases of piglets, and can replace antibiotics to be applied to the micro-ecological viable bacterium preparation.
Resumen de: CN121400487A
The invention discloses a novel anti-salmonella nano preparation CCJY as well as a preparation method and application thereof. The preparation comprises chitosan nano particles. The chitosan nanoparticle comprises cross-linked chitosan, and a lasso peptide MccJ25 and a lasso peptide MccY which are loaded on the chitosan. According to the invention, the synergistic antibacterial effect among different lasso peptides is exerted through a chemical cross-linking technology, on the basis of integrating the original antibacterial types of the lasso peptide MccJ25 and the lasso peptide MccY, the antibacterial types are expanded to serratia marcescens and enterococcus cloacae, and the broad-spectrum antibacterial effect is realized. Meanwhile, the invention further discloses a preparation method and application of the chitosan nano-particles and an anti-salmonella nano-preparation containing the chitosan nano-particles.
Resumen de: CN121401341A
The invention belongs to the field of veterinary drugs, and particularly relates to a composite pharmaceutical composition for preventing and treating avian salmonella infection and application of the composite pharmaceutical composition. The composition comprises the following components in parts by weight: florfenicol, coptis chinensis and schisandra chinensis extract, vitamin C and prebiotics. Florfenicol and specific traditional Chinese medicines are combined and matched with sufficient vitamin C and prebiotics to form an antibacterial-protection-repair three-in-one synergistic system. On the premise of remarkably reducing the dosage of florfenicol, the compound can achieve a better clinical curative effect, relieve toxic and side effects and promote rapid rehabilitation of infected poultry, has obvious comprehensive advantages and is suitable for preparing a medicine for preventing and treating avian salmonellosis.
Resumen de: CN121406803A
The invention establishes a method for simultaneously detecting vibrio parahaemolyticus, staphylococcus aureus, listeria monocytogenes, salmonella, shigella, bacillus cereus and vibrio alginolyticus on the basis of multiple PCR (Polymerase Chain Reaction) combined with a gene chip technology. The method comprises the following steps: selecting a heat-labile hemolysin gene of vibrio parahaemolyticus, a heat-resistant nuclease gene of staphylococcus aureus, a coded hemolysin O gene hlyA of listeria monocytogenes, an invasive protein A gene of salmonella enteritidis and an invasive plasmid antigen H gene of Shigella to carry out quintuple PCR (Polymerase Chain Reaction) amplification; bacillus cereus non-hemolytic toxin genes and vibrio alginolyticus similar Rpos sigma factor genes are selected for double PCR, two groups of multiplex PCR amplification products are hybridized with specific probes on the chip at the same time, and seven food-borne pathogenic bacteria can be detected at the same time. The method for detecting pathogenic bacteria by using the gene chip is high in specificity, high in sensitivity and strong in reliability.
Resumen de: CN121380030A
The invention belongs to the technical field of antibiotic enzymes, and relates to a recombinant antibiotic enzyme PlyTC37 as well as a coding gene and application thereof. The amino acid sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 1, and the coding nucleotide sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 2. The recombinant antibiotic enzyme PlyTC37 disclosed by the invention has a wider bactericidal spectrum, so that the recombinant antibiotic enzyme PlyTC37 has a killing effect on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa and gram-positive bacteria such as staphylococcus aureus, streptococcus agalactiae and streptococcus hemolyticus, the MIC value of the recombinant antibiotic enzyme PlyTC37 to acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa is about 20 mu g/ml. Meanwhile, the recombinant antibiotic enzyme PlyTC37 enables the load of acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa to be reduced by 4-5 logarithmic units in the presence of NaCl with physiological concentration, so that the clinical application prospect of the recombinant antibiotic enzyme PlyTC37 is remarkably improved.
Resumen de: CN121379980A
The invention discloses a salmonella bacteriophage SaPA-9 with a wide host spectrum and application of the salmonella bacteriophage SaPA-9. The preservation number of the salmonella bacteriophage SaPA-9 with the wide host spectrum is GDMCC No: 63416-B1. The bacteriophage SaPA-9 has an ultra-wide host spectrum, not only has a relatively strong killing effect on salmonella, but also plays a role in escherichia coli, has genome safety and in-vivo and in-vitro safety, is suitable for large-scale salmonella or escherichia coli infection resistance, and has a better application effect.
Resumen de: CN121380278A
The invention discloses a salmonella sodium hypochlorite tolerance evaluation method, which comprises: (1) preparing a bacterial liquid, and (2) carrying out a cell viability chromogenic reaction: adding 100 mu L of a bacterial suspension and 100 mu L of a sodium hypochlorite solution with a gradient concentration into each well of a 96-well plate, standing for 30 min under a room temperature condition, adding 20 mu L of a 2.5 wt% sodium thiosulfate solution, standing for 10 min under a room temperature condition, and carrying out a cell viability chromogenic reaction, adding 20 mu L of a 10 * resazurin indicator, and culturing at a constant temperature of 37 DEG C for 4 h; and (3) salmonella tolerance grade determination based on the MIC value: taking the lowest sodium hypochlorite concentration of blue pores in a 96-pore plate as the MIC value, and the higher the MIC value is, the stronger the tolerance is. According to the method, the tolerance of the salmonella to the sodium hypochlorite can be intuitively and quickly judged through the chromogenic reaction.
Resumen de: CN121379903A
The invention relates to the technical field of microorganisms, and particularly discloses a lactobacillus paracasei KQNIU, a microbial preparation and application of the lactobacillus paracasei KQNIU. The Lactobacillus paracasei KQNIU is preserved in the China General Microbiological Culture Collection Center on August 25, 2025, the preservation number is CGMCC No.35739, and the Lactobacillus paracasei KQNIU is classified and named as Lactobacillus paracasei, and the Lactobacillus paracasei KQNIU is named as Lactobacillus paracasei KQNIU. The Lactobacillus paracasei KQNIU is named as Lactobacillus paracasei KQNIU. The lactobacillus paracasei KQNIU provided by the invention has good gastrointestinal tract tolerance, has an inhibition effect on pathogenic bacteria such as escherichia coli, salmonella and the like, can be prepared into a microbial preparation or a feed additive for preventing and treating calf diarrhea, replaces antibiotics and realizes green and healthy breeding.
Nº publicación: CN121399274A 23/01/2026
Solicitante:
生物梅里埃公司
Resumen de: WO2025003117A1
The present invention relates to a gelled reaction medium for detecting, identifying, and/or isolating at least one Shiga toxin-producing strain of E. coli, the reaction medium comprising: - at least one toxin inducer, - at least one agglutinating conjugate comprising at least one specific binding partner of STX1 and/or at least one specific binding partner of STX2, coupled to a nanoparticle; - a concentration gradient of a compound for inhibiting non-target bacteria. The present invention also relates to the associated method for detecting and/or isolating Shiga toxin-producing E. coli which is likely to be present in a sample comprising enterobacteria.
BOPI
Sede Electrónica
